DANIEL LEBOVITS: Open Payments
NPI 1013990936 · CORAL SPRINGS, FL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$732 in 38 payments from 13 companies in 2025. Trend: 2023 $1,249 · 2024 $802 · 2025 $732
Food & beverage: $732
| Company | Payments | Amount |
|---|---|---|
| Galderma Laboratories, L.P. | 12 | $151 |
| GENZYME CORPORATION | 5 | $145 |
| ABBVIE INC. | 4 | $74 |
| Janssen Biotech, Inc. | 2 | $50 |
| Amgen Inc. | 2 | $49 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 2 | $48 |
| Novartis Pharmaceuticals Corporation | 2 | $45 |
| Lilly USA, LLC | 2 | $45 |
| SUN PHARMACEUTICAL INDUSTRIES INC. | 2 | $40 |
| UCB, Inc. | 1 | $30 |
Products named: DUPIXENT, NEMLUVIO, SKYRIZI, TREMFYA, OTEZLA, SPEVIGO, ILUMYA, COSENTYX.
Industry payments across FL — which companies pay providers there.
